A Phase II Study of the CXCR2 Antagonist Navarixin in Combination with Pembrolizumab for Patients with Advanced Castration-Resistant Prostate Cancer, Microsatellite-Stable Colorectal Cancer, or Non-Small-Cell Lung Cancer. Here, CXCR2 is linked to non-small cell lung carcinoma.